共 97 条
[1]
Augood C(2004)Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study Ophthalmic Epidemiol 11 117-129
[2]
Fletcher A(2004)Age-related macular degeneration is the leading cause of blindness JAMA 291 1900-1901
[3]
Bentham G(2004)Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 564-572
[4]
Chakravarthy U(2004)Global data on visual impairment in the year 2002 Bull World Health Organ 82 844-851
[5]
de Jong PT(1984)Age-related macular degeneration and blindness due to neovascular maculopathy Arch Ophthalmol 102 1640-1642
[6]
Rahu M(2006)Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 1432-1444
[7]
Seland J(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431
[8]
Soubrane G(2008)Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 239-248
[9]
Tomazzoli L(2007)An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 566-583
[10]
Topouzis F(2009)A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 e41-256